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AngiotensinThe role of the central opioid system in the control of water and salt intake is complex,with both stimulatory and
inhibitory effects having been observed. The aim of the present study was to investigate the participation of the
central κ-opioid receptors in the control of salt appetite. MaleWistar rats were submitted to two different exper-
imental protocols: sodium deﬁcit produced by the diuretic, furosemide, and brain angiotensinergic stimulation
in rats under normal sodium balance. Lateral ventricle (LV) injections of Nor-binaltorphimine (Nor-BNI) at dif-
ferent doses (5, 10 and 20 nmol) inhibited hypertonic saline solution (1.5%) intake in sodium-depleted rats.
The salt appetite induced by an LV injection of angiotensin II (AngII) (10 ng) was also blocked by Nor-BNI injec-
tions into the LV, while no signiﬁcant change was observed in water intake. Furthermore, the decrease in salt
intake seems not to have been due to a general inhibition of locomotor activity or to any change in palatability,
since central administration of Nor-BNI failed to modify the intake of a 0.1% saccharin solution when the animals
were submitted to a “dessert test” or to induce any signiﬁcant locomotor deﬁcit in the open-ﬁeld test. Also the
central administration of Nor-BNIwas unable tomodify blood pressure in sodium-depleted animals. The present
results suggest that activation of endogenous κ-opioid receptors modulates salt appetite induced by sodium
depletion and by central angiotensinergic stimulation in rats.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The different families of opioid peptides include endorphins, en-
kephalins, dynorphins, and nociceptin/orphanin that act through
four major types of receptor: mu (μ), kappa (κ), delta (δ) and noci-
ceptin (N/OFQ). There is evidence of distinctive but overlapping dis-
tributions of μ, κ, δ and N/OFQ receptors in different areas of the
brain [1–7]. The endogenous opioid system is involved in a variety of
functions and is found in multiple networks throughout the brain,
especially in areas related to feeding and drinking behavior, cardiovas-
cular control and endocrine regulation [1,8]. The role of the brain opioid
system in regulating feeding behavior and modulating reward-related
responses and the palatability of different substances has been well-
documented [8–11]. The participation of the central opioid system in
the control of water and salt intake is rather complex, with both stimu-
latory and inhibitory effects having been observed depending on the
anatomical location, the type of opioid receptor involved and the
doses of the opioidergic agents used.. in Physiology, Full Professor.
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evier OA license.The physiological regulation of body sodium depends on a multi-
faceted mechanism involving homeostatic responses and palatability
and reward aspects of salt intake. Sodium deﬁcit motivates behavior
to speciﬁcally seek out and ingest the sodium ion [12–15]. Some stud-
ies have also shown the participation of endogenous opioid peptides
in salt preference. The antagonist opioid, naloxone, administered
both systemically and in the central nervous system, reduces the
intake of hypertonic, hypotonic and isotonic saline solutions which
are preferred overwater inwater-deprived rats [16–19]. Furthermore,
in water-deprived rats central administration of μ- and κ-antagonists,
but not δ-antagonists, decreases water intake in a two-bottle choice
test between water and saline solution (0.6% and 1.7%). However,
any of the antagonists used in this study were able to alter the intake
of saline solution [20]. Conversely, in non-deprived rats, saline intake
is increased by injecting selective δ-, μ- and κ-opioid agonists into the
cerebroventricular system and into the parabrachial nuclei [18,19,21].
In addition, systemic injections of morphine increase hypertonic
saline intake in sodium-depleted rats [22]. However, in this study,
the opioid agents were administered subcutaneously after repeated
sodium depletion. It has been shown that repeated sodium depletion
may alter the intake of saline solution [23,24], as well as the palatability
of salty solutions. Further studies are necessary to clarify the role of the
different central opioid peptides receptors in the control of salt appetite.
Because of the contradictions in the literature with respect to the
participation of opioid receptors, particularly the k-opioid receptors,
in salt appetite, the objective of the present study was to investigate
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appetite in two different models: 1) sodium deﬁciency produced by
single administration of the diuretic, furosemide; 2) cerebral admin-
istration of a natriorexigenic drug, angiotensin II, in rats with normal
sodium balance; two approaches that have largely been used in the
literature to study salt preference. In addition, the effect of central
k-opioid receptor blockade on locomotor activity, on palatable solution
intake (0.1% saccharin) and on blood pressure was investigated. The
hypothesis evaluated in this study is that opioid peptides are released
during homeostatic challenges and that interaction with κ-opioid
receptors may modulate different aspects of salt intake (homeostatic,
palatability and reward) in order to correct sodium imbalance.
2. Methods
2.1. Animals
Adult male Wistar rats weighing 220–250 g were used in the pre-
sent study and kept under controlled light (lights on from 5 AM to
7 PM) and temperature (22±2 °C) conditions. They had free access
to tap water and laboratory chow (Nuvital Nutrientes Ltda., Curitiba,
Brazil). Groups of rats used in one experimental set were not reused
in any other part of the study. All experiments were conducted be-
tween 7 AM and 11 AM. The experimental protocols were performed
according to the regulations established by the National Council for
the Control of Animal Experiments (Conselho Nacional de Controle de
Experimentação Animal — CONCEA, Brazil).
2.2. Surgical procedures
Five days before the experimental sessions the animals were anes-
thetized with ketamine/xylazine (80/7 mg/kg i.p.) to enable a guide
cannula (22-gauge) to be implanted into the lateral ventricle (LV)
according to the following coordinates: anteroposterior=0.9 mm be-
hind the bregma; lateral=1.5 mm; vertical=4.0 mmbelow the skull.
The guide cannula was ﬁxed to the skull with metal screws and dental
cement. To avoid obstruction of the guide cannula, an obturator was
provided. After surgery, the animals were housed in individual cages
and had free access to two different bottles, one containing distilled
water and the other containing hypertonic saline solution (1.5%).
The animals were handled every day in order to minimize the stress
of the experimental procedure. The location of the guide cannula in
the LV and the intracerebroventricular injection site was conﬁrmed
at the end of the experiment with the use of Evans Blue dye injected
through the cannula. The brains were removed, placed in formalin,
and later frozen and cut into 40 μm sections. The slices were stained
with cresyl violet and analyzed using light microscopy. Only data
from the animals in which the tip of the cannula was restricted to
the cerebroventricular space and the Evans Blue dye could not be
seen in the brain tissue surrounding the ventricle were included in
the study.
2.3. Drugs and microinjections
The drugs used were Nor-binaltorphimine (Nor-BNI), an opioid
antagonist selective to κ-opioid receptors [25,26], ICI199,441 an opioid
agonist preferentially binding to κ-opioid receptors [27], both ac-
quired from Tocris Bioscience, Ellisville, MO, USA, and angiotensin II
(AngII), which was purchased from Sigma Chemical, Co., St. Louis,
MO, USA. The doses of the drugs used in this study were compatible
with those used by other research groups: the doses of Nor-BNI
were 5, 10 and 20 nmol/rat [20], while the dose of ICI199,441 was
9.4 nmol/rat [28] and the dose of AngII was 10 ng/rat [29]. pH was
neutral in all solutions and no acid or basic solutions were injected.
Central injections were given using a Hamilton microsyringe con-
nected to a 30-gauge injector through polyethylene tubing (PE10).A total volume of 2 μl was slowly injected (60 s). Furosemide, a loop
diuretic, was purchased from Sanoﬁ-Aventis Ltd., São Paulo, Brazil.
2.4. Sodium depletion (experiments 1 and 2)
Animals received a subcutaneous injection of furosemide (10 mg/kg)
to induce renal sodium loss 24 h prior to the experimental sessions.
After the injections, the rats had free access to distilled water and the
standard rat chow was replaced by a low sodium diet (0.001% Na
+and 0.33% K+). Control animals not submitted to sodium depletion
received subcutaneous injections of isotonic saline solution instead of
furosemide. In experiment 1, the participation of central kappa opioid
receptors in the salt appetite of sodium-depleted rats was tested in
different groups of sodium-depleted animals receiving LV injections of
Nor-BNI at different doses (5, 10 and 20 nmol). In experiment 2, another
group of sodium-depleted animals received an LV injection of 20 nmol
of Nor-BNI plus ICI199,441, a κ-opioid receptor agonist, at a dose of
9.4 nmol, to conﬁrm the speciﬁcity of Nor-BNI. Sodium-depleted control
animals received LV injections of isotonic saline solution. Bottles
containing hypertonic saline solution (1.5%) and distilled water were
reintroduced into the cages 15 min after the injections. The ﬁrst mea-
surement of ﬂuid intake was recorded 5 min after this and measure-
ments continued for the next 120 min. In an additional control group,
the animals received subcutaneous injections of isotonic saline solution
instead of furosemide and LV injections of isotonic saline solution.
2.5. Central angiotensinergic stimulation (experiment 3)
To study the participation of κ-opioid receptors in water and salt
intake under conditions of normal sodium balance, pharmacological
stimulation of central angiotensinergic pathways was performed. Dif-
ferent groups of rats received LV injections of Nor-BNI at different
doses (5, 10 and 20 nmol) 15 min before receiving AngII (10 ng/rat).
Bottles containing 1.5% saline solution and distilled water were
made available immediately after the LV injections of AngII. As in
the previous experimental sets, the ﬁrst measurement of ﬂuid intake
was recorded 5 min afterwards and measurement continued for the
next 120 min. In an additional control group, the animals received
central administration of saline instead of AngII.
2.6. Open ﬁeld test (experiment 4A)
Different groups of rats receiving LV injections of Nor-BNI
(20 nmol) or saline solution were submitted to an open ﬁeld test to
exclude the possibility that this agent could have induced a locomotor
alteration that would explain the inhibition of salt intake observed
here. In this test, the animals were placed in a circular acrylic box
(60 cm in diameter and 60 cm high) with an open top 30 min after an
injection of Nor-BNI or saline solution into the LV. The ﬂoorwas divided
into eight areas of equal sizewith a circle at the center (42.43 cm). Hand
operated counters and stopwatcheswere used to score locomotion over
a 10 min period by measuring the number of areas into which the rats
entered with all four paws. The behavioral experiments took place in
a sound-attenuated, temperature-controlled (24±1 °C) room between
7 AM and 11 AM. A white-noise generator provided constant back-
ground noise and the apparatus was cleaned with 70% ethanol and
dried before each session to minimize olfactory cues.
2.7. Dessert test (experiment 4B)
The effect of an LV injection of Nor-BNI on the intake of a 0.1% sac-
charin solution, a well-established model of hedonic behavior in rats
[30], was used to exclude the possibility of a non-speciﬁc, general in-
hibition of the central nervous system induced by this agent. In this
experiment, after LV cannulation the animals were kept in the usual
individual cages during the training period with free access only to
Fig. 1. Cumulative salt (panel A) and water intake (panel B) following lateral ventricle
injections of Nor-BNI at different doses (5, 10 and 20 nmol) or saline in sodium-
depleted (SD) rats. An additional group of animals not submitted to sodium depletion,
receiving lateral ventricle injections of saline, is also shown (normonatremic). The
pharmacological treatment and the number of animals used in each group are shown
in panel B. Data are presented asmeans+SEM (error bar above). The letter “a” indicates
a statistically signiﬁcant difference (one-way ANOVA followed by Student–Newman–
Keul's test; pb0.05) when the different groups are compared to sodium-depleted ani-
mals receiving saline at each measurement period. The letter “b” indicates a statistically
signiﬁcant difference when the different groups are compared to sodium-depleted rats
receiving 20 nmol of Nor-BNI at each measurement period. Each bar in the graph was
obtained from a naïve group of animals.
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2 h each day for seven consecutive days. In the test cage the animals
had access to two bottles containing water and 0.1% saccharin solu-
tion. After this training period, the animals were divided into two
groups and were deprived of ﬂuid for 24 h. Afterwards, the animals
received LV injections of Nor-BNI (20 nmol) or saline (controls)
15 min before being transferred to the test cage, and water and sac-
charin intake was recorded over a 120 min period.
2.8. Blood pressure recording (experiment 5)
One day before the experimental sessions, a catheter (PE50) ﬁlled
with heparin solution (1000 U/ml) was inserted into the left carotid
artery under ketamine/xylazine anesthesia, and exteriorized at the
nape of the animal's neck to permit blood pressure recording. At the
experimental session, the carotid catheter was connected to a pres-
sure transducer whose signal was ampliﬁed and digitally recorded
by an analog-to-digital interface (AqDados, version 5, Lynx Tecnolo-
gia Eletrônica LTDA, São Paulo, Brazil) and recorded (1 kHz) on a
microcomputer for posterior analysis. Distinct groups of sodium-
depleted animals received an LV injection of Nor-BNI (20 nmol) or
saline solution (controls) 10 min after baseline blood pressure was
recorded. In each of these groups, blood pressure continued to be
recorded for the next 120 min after Nor-BNI or saline solution was
injected. The experimental protocol used in this case was identical
to that used to study salt intake in the previous groups. Mean arterial
pressure (MAP) was calculated from systolic and diastolic pressure
measurements using the AcqKnowledge software program, version
3.5.7, developed by Biopac Systems, Inc., California, USA. The MAP
values at the end of the stabilization period (time zero) were used
as references to calculate the delta values that are presented through-
out the experiments.
2.9. Statistical analysis
The data are presented as means±SEM. Statistical analyses were
performed using the GraphPad Prism software (GPAD, version 5.0,
San Diego, USA). To compare the effect of each treatment on sodium
appetite, the cumulative water and sodium intake were analyzed
using one-way ANOVA followed by the Student–Newman–Keul's
post-hoc test at each measurement interval. Student's t-test was
used to analyze the data obtained in the open ﬁeld and dessert
tests. The delta values of MAP were analyzed using two-way repeated
measures ANOVA followed by the post-hoc Bonferroni test. Differ-
ences between the groups were considered statistically signiﬁcant
when pb0.05
3. Results
3.1. Experiment 1 — Central effect of a kappa opioid receptor antagonist
on salt appetite in sodium-depleted rats
Fig. 1 (panel A) shows the effect of LV injections of Nor-BNI at the
doses of 5 (n=6), 10 (n=14) and 20 nmol (n=14) on cumulative
salt intake in sodium-depleted rats. As expected, the intake of hyper-
tonic saline was signiﬁcantly lower in each measurement period in
the normonatremic animals receiving LV injections of isotonic saline
(n=9) when compared to sodium-depleted rats also receiving LV in-
jections of isotonic saline (n=10). The blockade of central κ-opioid
receptors by LV injection of the antagonist Nor-BNI induced a dose-
dependent inhibition of salt intake in sodium-depleted rats. At the
highest dose used (20 nmol), Nor-BNI signiﬁcantly inhibited salt
intake in the sodium-depleted rats when compared to the sodium-
depleted control group. This inhibition of salt intake was evident in
all the measurement periods, beginning at the 0–15 min measure-
ment period. At the intermediate dose of Nor-BNI (10 nmol), saltintake was signiﬁcantly inhibited compared to that of the sodium-
depleted animals treated with isotonic saline. In this case, inhibition
started at the 0–30 min measurement period and persisted until the
end of the experiment. The salt intake in sodium-depleted rats receiv-
ing an LV injection of Nor-BNI at the lowest dose (5 nmol) was similar
to that found in the group of sodium-depleted rats receiving LV injec-
tions of isotonic saline. Furthermore, the salt intake in sodium-
depleted rats receiving 5 nmol of Nor-BNI was signiﬁcantly different
throughout the entire experimental period compared to that of the
animals treated with Nor-BNI at the dose of 20 nmol. The one-way
ANOVA results are: 15 min — F(4,48)=8.617, pb0.0001; 30 min —
F(4,48)=10.50, pb0.0001; 60 min F(4,48)=19.99, pb0.0001; 90 min
F(4,48)=19.35, pb0.0001; 120 min F(4,48)=17.34, pb0.0001.
Fig. 1 (panel B) shows the effect of LV injections of Nor-BNI at the
doses of 5, 10 and 20 nmol on water intake in sodium-depleted rats.
Fig. 2. Cumulative salt (panel A) and water intake (panel B) in sodium-depleted ani-
mals pretreated with lateral ventricle injections of ICI199,441 (9.4 nmol) or saline before
receiving central administration of Nor-BNI (20 nmol), and in control animals receiving
two subsequent lateral ventricle injections of saline. An additional group of animals not
submitted to sodium-depletion, receiving two subsequent lateral ventricle injections of
saline, is also shown (normonatremic). The pharmacological treatment and the num-
ber of animals used in each group are shown in panel B. Data are presented as
means+SEM (error bar above). The letter “a” indicates a statistically signiﬁcant differ-
ence (one-way ANOVA followed by Student–Newman–Keul's test; pb0.05) when the
different groups are compared to sodium-depleted animals receiving saline+saline
at each measurement period. The letter “b” indicates a statistically signiﬁcant differ-
ence when the different groups are compared to sodium-depleted rats receiving
20 nmol of Nor-BNI+saline at each measurement period. Each bar in the graph was
obtained from a naïve group of animals.
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remained unaltered by any of the treatments. The one-way ANOVA
results are: 15 min — F(4,48)=0.301, p=0.876; 30 min — F(4,48)=
1.009, p=0.412; 60 min — F(4,48)=1.129, p=0.354; 90 min —
F(4,48)=0.881, p=0.482; 120 min — F(4,48)=0.905, p=0.469.
3.2. Experiment 2 — Central effect of the kappa opioid receptor agonist,
ICI199,441, on the inhibitory action of Nor-BNI on salt appetite in
sodium-depleted animals
Fig. 2 (panel A) illustrates the effect of ICI199,441 (9.4 nmol, n=13)
on the inhibition of salt intake induced by Nor-BNI (20 nmol, n=11)
in sodium-depleted rats. As expected, saline-treated normonatremic
animals (n=9) drank signiﬁcantly less hypertonic saline compared
to sodium-depleted rats also receiving LV injections of isotonic saline
(n=10). As in the previous experiment, at the dose of 20 nmol, Nor-
BNI exerted a signiﬁcant inhibitory effect on salt intake throughout
the entire measurement period compared to sodium-depleted rats
receiving isotonic saline injections. Cumulative salt intake was signif-
icantly higher at all measurement periods in sodium-depleted rats re-
ceiving 9.4 nmol of ICI199,441 but pretreated with 20 nmol of Nor-BNI
(n=15) compared to the group treated with Nor-BNI alone. Indeed
the amount of salt intake in this group (Nor-BNI+ICI199,441) was sim-
ilar to that observed in saline-treated, sodium-depleted rats in each
measurement period. Central administration of ICI199,441 alone failed
to alter salt intake when compared to saline-treated, sodium-depleted
rats. The one-way ANOVA results are: 15 min — F(4,53)=8.611,
pb0.0001; 30 min — F(4,53)=15.75, pb0.0001; 60 min — F(4,53)=
27.26, pb0.0001; 90 min — F(4,53)=23.24, pb0.0001; 120 min —
F(4,53)=26.14, pb0.0001.
Fig. 2 (panel B) shows the effect of LV injections of the κ-opioid
antagonist (Nor-BNI 20 nmol) plus the agonist (ICI199,441 9.4 nmol)
on water intake in sodium-depleted rats. As expected, water intake
was very low in sodium-depleted rats and remained unaltered by any
of the treatments. The one-way ANOVA results are: 15 min — F(4,53)=
1.478, p=0.222; 30 min — F(4,53)=1.462, p=0.227; 60min —F(4,53)=
1.006, p=0.413; 90 min — F(4,53)=1.176, p=0.332; 120 min —
F(4,53)=0.709, p=0.589.
3.3. Experiment 3— Central effect of kappa opioid receptor antagonist on
salt appetite induced by angiotensin II
Fig. 3 (panel A) shows the effect of LV injections of Nor-BNI at the
doses of 5 (n=9), 10 (n=14) and 20 nmol (n=10) on cumulative
salt intake induced by central angiotensinergic stimulation in rats. The
blockade of central κ-opioid receptors impairs the salt intake induced
by stimulation of the central angiotensinergic system in a dose-
dependent way. Predictably, salt intake was very low in animals receiv-
ing an LV injection of isotonic saline (n=9) throughout the entire dura-
tion of the experiment (0.3±0.2 ml/100 g b.w.), while salt intake was
high in animals treated with 10 ng of AngII (n=10), beginning at the
0–15 min measurement period and lasting throughout the 0–120 min
period (5.4±0.27 ml/100 g b.w.). The salt intake induced by AngII
was signiﬁcantly inhibited by pretreatment with Nor-BNI at the dose
of 20 nmol beginning at the 0–30 min period and lasting throughout
the 0–120 min period (1.1±0.6 ml/100 g b.w.). At the intermediate
dose, Nor-BNI (10 nmol) pretreatment also inhibited salt intake in-
duced by AngII and the amount of salt intake at the 0–120 min period
was 2.6±0.66 ml/100 g b.w. The salt intake in animals pretreated
with the lowest dose of Nor-BNI (5 nmol) and receiving AngII was sim-
ilar to that of the group pretreated with saline (saline+AngII). Further-
more, in this group, salt intake was signiﬁcantly different from that
found in the animals pretreated with Nor-BNI at the dose of 20 nmol
at the 0–90 min measurement period and this difference persisted
until the end of the experiment (3.9±0.55 ml/100 g b.w.). The one-
way ANOVA results are: 15 min — F(4,47)=3.892, p=0.008; 30 min —F(4,47)=6.305, p=0.0004; 60 min — F(4,47)=8.865, pb0.0001;
90 min— F(4,47)=12.53, pb0.0001; 120 min— F(4,47)=14.27, pb0.0001.
Fig. 3 (panel B) shows the effect of LV injections of Nor-BNI at the
doses of 5, 10 and 20 nmol on water intake induced by central angio-
tensinergic stimulation in rats. As expected, in rats receiving a LV in-
jection of isotonic saline, water intake was very low throughout the
entire duration of the experiment (0.3±0.2 ml/ 100 g b.w.), while
water intake was higher in animals treated with 10 ng of AngII begin-
ning at the 0–15 min measurement period and lasting until 120 min
(5.3±0.9 ml/100 g b.w.). Nor-BNI failed to alter water intake induced
by LV injection of AngII (10 ng) at any of the doses used (5, 10 or
20 nmol) throughout the entire period of the experiment. The one-way
ANOVA results are: 15 min — F(4,47)=2.923, p=0.031; 30 min —
F(4,47)=5.656, p=0.0008; 60 min — F(4,47)=6.327, p=0.0004;
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Fig. 3 (panel C) shows the percentage of total ﬂuid intake as water
and hypertonic saline at the end of the experimental session (120 minafter reintroduction of the bottles into the cages). One-way ANOVA
values are F(7,72)=10.46, pb0.0001. Unlike the previous experimental
sets, during this experimental session, central angiotensinergic stimu-
lation induces both water and salt intake. In the group pretreatedwith
Nor-BNI at the dose of 5 nmol the amount of salt intake was similar to
the amount of water intake. However, at the doses of 10 and 20 nmol,
salt intakewas signiﬁcantly lower (30.2% and 14.5% respectively) than
water intake (69.8% and 85.5% respectively).
3.4. Experiment 4 — Central effect of the kappa opioid receptor antago-
nist on locomotor activity and hedonic behavior in rats
Fig. 4 (panel A) shows the results of the open ﬁeld test. Central
blockade of κ-opioid receptors failed to alter locomotor activity in
sodium-depleted rats. Locomotor behavior was similar in the group
treated with an LV injection of Nor-BNI at the dose of 20 nmol
(n=10) and in the group of sodium-depleted animals receiving LV
injections of saline solution (n=11).
Fig. 4 (panel B) shows the results of the dessert test. The hedonic
behavior represented by preference for a palatable solution was con-
ﬁrmed by the higher saccharin intake compared to water intake in
saline-treated control animals. At the dose of 20 nmol, Nor-BNI
(n=6) injected into the LV failed to alter this hedonic preference. In-
deed, animals receiving this κ-opioid antagonist drank similar amounts
of saccharin (6.8±0.5 ml/100 g b.w.) and water (3.4±1.0 ml/100 g
b.w.) as saline-treated controls (saccharin=7.5±0.7 ml/100 g b.w.
and water=3.4±1.2 ml/100 g b.w.; n=7).
3.5. Experiment 5 — Central effect of the kappa opioid receptor antago-
nist on blood pressure in sodium-depleted rats
Fig. 5 shows the effects of Nor-BNI (20 nmol, n=8) on blood pres-
sure in rats submitted to sodium depletion using the same experi-
mental protocol used to study salt intake. In this situation, central
administration of Nor-BNI failed to modify blood pressure in sodium-
depleted animals compared to sodium-depleted controls (saline-treated,
n=6) throughout the entire experimental period.
4. Discussion
In the present study, the data obtained clearly show that: 1) phar-
macological blockade of central κ-opioid receptors by a selective an-
tagonist, Nor-BNI, results in a signiﬁcant decrease in salt intake in
sodium-depleted rats; 2) the blockade of those receptors also inhibits
the salt intake induced by central angiotensinergic stimulation; 3) the
inhibitory effect on salt intake in sodium-depleted rats induced by the
blockade of central κ-opioid receptors is impaired by central adminis-
tration of a κ-opioid receptors agonist; 4) the dessert test revealed
that the hedonic ingestive behavior of a palatable saccharin solutionFig. 3. Cumulative salt (panel A) and water intake (panel B) in animals pretreated with
lateral ventricle injections of Nor-BNI at different doses (5, 10 and 20 nmol) or saline
prior to receiving central administration of 10 ng of angiotensin II (Ang II) and in con-
trol animals receiving two subsequent lateral ventricle injections of saline. The phar-
macological treatment and the number of animals used in each group are shown in
panel A. Data are presented as means+SEM (error bar above). The letter “a” indicates
a statistically signiﬁcant difference (one-way ANOVA followed by Student–Newman–
Keul's test; pb0.05) when the different groups are compared to the group of animals
receiving saline+AngII at each measurement period. The letter “b” indicates a statisti-
cally signiﬁcant difference when the different groups are compared to rats receiving
20 nmol of Nor-BNI+AngII at each measurement period. The letter “c” indicates a sta-
tistically signiﬁcant difference when the different groups are compared to the group of
animals receiving saline+saline at each measurement period. Each bar in the graph
was obtained from a naïve group of animals. panel C shows the percentage of total
ﬂuid consumed as water and saline at the end of the experimental session (120 min)
in the same groups shown in panels A and B. ∗ indicates a statistically signiﬁcant differ-
ence (one-way ANOVA followed by Student–Newman–Keul's test; pb0.05) when the
percentage of water intake is compared with the percentage of hypertonic saline in-
take in each group.
Fig. 4. Panel A shows the number of areas entered over a 15 min periods in the “open
ﬁeld” test carried out in rats receiving lateral ventricle injections of Nor-BNI (20 nmol)
or isotonic saline solution (controls). The treatment received by each group and the
number of animals used is indicated in the graph. Data are expressed as means+
SEM (error bar above). There was no statistically signiﬁcant difference (t-test;
pb0.05) between the group of animals receiving Nor-BNI and the saline-treated ani-
mals. Panel B shows cumulative saccharin and water intake (ml/100 g body weight)
over a 2-h period in the test cage in rats receiving lateral ventricle injections of Nor-
BNI (20 nmol) or isotonic saline solution (controls). The treatment received by each
group and the number of animals used is indicated in the graph. Data are expressed
as means+SEM (error bar above). There was no statistically signiﬁcant difference
(t-test; pb0.05) when the group of animals receiving Nor-BNI was compared to controls.
Fig. 5. Changes in mean blood pressure in sodium-depleted rats after injections of Nor-
BNI (■ 20 nmol; n=8) or saline solution (□; n=6), into the lateral ventricle. Blood
pressure recording between−10 and 0 min corresponds to a pre-drug baseline evalu-
ation. The injections were given at 0 min and the bottles containing water and saline
solution (1.5%) were immediately accessible. Data are presented as means+SEM
(error bar above). There was no statistically signiﬁcant difference between the groups
(two-way ANOVA followed by Bonferroni test; pb0.05).
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ceptors; 5) the open ﬁeld test showed that central blockade of
κ-opioid receptors did not reduce locomotor activity; 6) the blockade
of central κ-opioid receptors failed to modify blood pressure in ani-
mals submitted to sodium-depletion.
One of the procedures used here to induce salt intake was sodium-
depletion, which was achieved by subcutaneous administration of the
diuretic, furosemide. This is a classic model for inducing salt appetite
and during the experimental sessions the animals had access to bothdistilled water and saline solution in a concentration that is usually
aversive to rats [31,32]. Furosemide treatment depletes the animal
of both sodium and water. With the experimental paradigm used
here, water intake is permitted (overnight) prior to allowing access
to saline solution. During the experiments, only salt intake was
recorded, since water deﬁcit was largely restored before access to
saline was provided. In the two-bottle choice test between water
and saline solution, as expected water intake was found to be very
low compared to salt intake, which demonstrated a clear preference
for salt. When sodium-depleted animals are treated with central
injection of Nor-BNI at the doses of 10 (intermediate dose) and
20 nmol (highest dose), salt preference is inhibited. Although, there
is a decrease in the total ﬂuid intake, this is mainly due to the
decrease in salt intake and not to a disproportional inhibition in salt
and water intake.
Different brain neurotransmitters, including endogenous opioids,
may mediate the palatability as well as the preference for speciﬁc
macronutrients and ﬂuid solutions [33–39]. The majority of studies
have shown the involvement of central opioid peptides in regulating
preference for sweet-tasting ﬂuids [40,41]. However, some studies
have also shown the participation of endogenous opioid peptides in
salt preference. The blockade of opioid receptors with naloxone
reduces the intake of hypertonic, hypotonic and isotonic saline
solutions in water-deprived rats [16–19]. On the other hand, central
stimulation of κ-, μ- and δ-opioid receptors increases saline intake
in non-deprived rats [18,19,21]. In addition, in rats submitted to
repeated sodium depletion, systemic injections of morphine increase
hypertonic saline intake [22]. It has been shown that the quantity of
saline solution ingested and the palatability of salty solutions are
altered by repeated sodium depletion [23,24].
In the present study, central injection of Nor-BNI decreased the
salt intake induced by sodium-depletion in a dose-dependent way.
In contrast, another research group reported that central injections
of Nor-BNI in ﬂuid-deprived (24 h) animals failed to change either
hypotonic or hypertonic saline intake [20]. In that study, the investi-
gators recorded the amount of ﬂuid intake only 3 h after a central in-
jection of Nor-BNI, while in the present study salt and water intake
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15 min after the ﬂuid bottles were reintroduced into the cages the
amount of hypertonic saline intake was signiﬁcantly lower in the an-
imals treated with the highest dose of Nor-BNI (20 nmol) compared
to saline-treated, sodium-depleted control animals. Although there
was a slight increase in salt intake at the end of the experimental ses-
sion (2 h) in Nor-BNI-treated animals, it never reached the amount of
salt drunk by the control group. Another essential difference between
the previous data and the present ﬁndings concerns the experimental
protocol used to induce salt appetite, ﬂuid deprivation and sodium-
depletion respectively. These conditions may trigger diverse mecha-
nisms that culminate with salt intake, which may explain the
inhibition in salt intake in sodium-depleted animals, but not in
ﬂuid-deprived rats after κ-opioid receptors blockade. These data sug-
gest that central κ-opioid receptor may modulate salt appetite in
sodium-depleted rats.
The selectivity of Nor-BNI for κ-opioid receptors has been shown
both in vitro and in vivo [42–44]. Nor-BNI is able to block the effect of
the κ-opioid receptor agonist, ICI199,441 in vivo and in vitro [45,46].
Also, the effect of another κ-opioid receptor agonist U69,593 on neuro-
nal activity is blocked by Nor-BNI with an apparent equilibriumdissoci-
ation constant (Ki) of 0.26 nM, as determined by the Schild analysis in
the electrophysiological assay. Furthermore, in a binding study, Nor-
BNI presented a Ki of 0.24 nM, as measured by radioligand binding dis-
placement [42]. The κ-opioid receptor agonist, ICI199,441, has been
shown to have a high afﬁnity and selectivity for the κ-opioid receptors
and is 146-foldmore active thanU-50488 in vitro in themouse vas defe-
rens model. Furthermore, it was found to exert potent naloxone-
reversible analgesic effects (ED50=0.004 mg/kg sc) in an abdominal
constriction model [47,48]. In the present study, central administration
of the κ-opioid receptor agonist, ICI199,441, was unable to alter salt intake
in sodium-depleted rats. However, since sodium-depleted rats drink a
large amount of hypertonic saline, it is unlikely that pharmacological
stimulation of κ-opioid receptors would further increase the volume
of hypertonic saline intake. In contrast, in sodium-depleted rats pre-
treated with Nor-BNI, a competitive antagonist of κ-opioid receptors,
and receiving central administration of ICI199,441, the inhibitory effect
of the central κ-opioid receptors blockade was reverted. These physio-
logical data from the present study suggest that the ICI199,441 may
have displaced the binding of Nor-BNI to the κ-opioid receptors. How-
ever further pharmacological and/or biochemical studies need to be
performed to conﬁrm this hypothesis.
In the present study, the effect of κ-opioid receptors on ingestive
behavior seems to be speciﬁc for sodium appetite since the water in-
take induced by AngII remained unchanged by Nor-BNI pretreatment,
while salt intake was inhibited in a dose-dependent way. Analyzing
the percentage of water and salt intake relative to the total amount
of ﬂuid intake, it is clear that central administration of Nor-BNI at
the doses of 10 and 20 nmol inhibits the preference for salt induced
by central AngII stimulation. These data conﬁrm the functional effect
of κ-opioid receptors speciﬁcally on the control of salt appetite.
The interaction between opiatergic and angiotensinergic systems
has already been shown, both at central and peripheral levels. At
peripheral level, naloxone has been shown to attenuate the pressor
response of an intravenous infusion of AngII [49]. Furthermore,
systemic naltrexone inhibits water intake induced by subcutaneous
AngII or hypertonic saline [50]. At central level, naloxone was found
to inhibit water intake induced by AngII [51,52]. Moreover, the
κ-opioid receptor antagonist, MR2266, injected intracerebroventricu-
larly, prevents the pressor effect and the alteration of baroreceptor
sensitivity induced by Ang II [53]. Conﬁrming this functional interac-
tion between the opiatergic and angiotensinergic systems, some
morphological data have shown a reciprocal synaptic relationship
between enkephalinergic and AngII neurons. In the area postrema,
presynaptic enkephalin axon terminals were found to make synapses
on the Ang perikarya and dendrites. On the other hand, AngII axonterminals also make synapses on the enkephalin perikarya and den-
drites, although this is less common than the aforementioned relation-
ship between these two neuronal pathways [54]. Therefore, it is
reasonable to afﬁrm that AngII modulates endogenous opioid peptide
release leading to increased sodium appetite, as suggested by the pre-
sent data.
Understanding the role of opioid peptides in brain function is a
rather complex matter. Endogenous opioids operate at many sites in
the brain through four opioid families, enkephalins, dynorphins, en-
dorphins and nociceptin/orphanin, interacting with different types
of receptors distributed widely throughout the brain [1–7]. It is note-
worthy that in areas of the brain related to the control of water and
salt intake such as the septal and preoptic areas, paraventricular nu-
clei, lateral hypothalamus, periventricular nuclei and amygdala the
density of μ, κ and δ receptors is moderate to high [2–4,55]. There is
evidence that both dopaminergic and opiatergic systems in the nucle-
us accumbens and ventral tegmental areas are involved in appetitive
behaviors and are associated with motivated behavior and drug-
abuse [8,41,56,57].
In the present study, Nor-BNI had no effect on saccharin intake in
the “dessert test”. This is in agreement with data published in the lit-
erature showing that intake of a palatable sucrose solution (10%) is
reduced by injections of a μ-opioid receptor antagonist but not a
κ-opioid receptor antagonist into the nucleus accumbens and ventral
tegmental area [39,58,59]. Opioid peptides acting in the nucleus
accumbens and ventral tegmental area have been shown to modulate
the hedonic/reward processing of ingestive behavior based on the
palatability of substances, while opioid peptides acting in the basolat-
eral amygdala are involved in the motivational and learning process
of ingestive behavior [60]. With respect to salt appetite, delta-opioid
receptors at the nucleus accumbens and ventral tegmental area
have been shown to participate in the control of salt intake [61]. In
the present study, the blockade of κ-opioid receptors appears not to
alter the palatability of the sodium solution (1.5%), and the inhibitory
effect of Nor-BNI on salt intake may involve a reward-independent
mechanism. However, further studies will have to be performed to
clarify the role of different opioid receptors in the brain areas control-
ling salt appetite.
It has been shown that locomotor activity may be affected by opioid
peptides. In general, μ- and δ-opioid receptors are associated with
hyperactivity, while activation of κ-opioid receptors decreases locomo-
tion [62]. In order to test the hypothesis that the decrease in salt intake
caused by the blockade of κ-opioid receptors was not due to a general
inhibition of locomotor activity, the open ﬁeld test was performed in
the present study. Results showed that locomotor activity was similar
in sodium-depleted animals receiving intracerebroventricular injec-
tions of Nor-BNI and in the sodium-depleted control animals. Therefore,
the inhibition of salt appetite induced by the blockade of κ-opioid
receptors is speciﬁc for this behavior and not a consequence of any loco-
motor impairment.
Endogenous opioids may also modulate cardiovascular responses,
although published data are not consistent, with both hypotension
and hypertension having been described [1,9,62]. In general, μ- and
δ-opioid receptors reduce blood pressure and heart rate [61]. Con-
cerning κ-opioid receptors, a hypertensive effect was observed fol-
lowing blockade of the κ-opioid receptors in anesthetized rats,
whereas in unanesthetized animals no change in blood pressure
was found [53,63,64]. In the present study, intracerebroventricular
injections of Nor-BNI had no effect on blood pressure in sodium-
depleted rats; hence the antinatriorexigenic effect induced by
κ-opioid receptor blockade is not due to a hypertensive response.
The data obtained in the present study may have clinical relevance
since both agonists and antagonist of κ-opioid receptors have been
used in different clinical intervention. It has been shown that κ-opioid
receptors are implicated in the control of food intake in animals models
of bulimia and binge-like eating [35–37] and pain mechanism and the
513A.I.R. Nascimento et al. / Physiology & Behavior 106 (2012) 506–514mediation of central and peripheral antinociception [65–68]. Further-
more, pharmacological manipulation of central κ-opioid receptors has
been used in current clinical practice to detoxify patients addicted to
opioids and maintain abstinence from illicit drugs [69–73]. In addition,
κ-opioid receptor antagonists may prove useful for the treatment of
depression,while κ-opioid receptor agonistsmay be useful for the treat-
ment of bipolar disorder or mania [74].
In conclusion, these data show that the blockade of central
κ-opioid receptors inhibits salt intake in two different models: sodi-
um depletion and brain angiotensinergic stimulation. The decrease
in salt intake does not appear to be due to a general inhibition of lo-
comotor activity or to any change in palatability. The present study
builds on and extends previous ﬁndings by Bodnar group [20] by in-
dicating that particular physiological conditions, sodium-depletion
and central angiotensinergic stimulation, are sensitive to κ-opioid re-
ceptor, whereas water deprivation is not.Acknowledgments
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